Business
PDMR Shareholding/SIP and TVR
PDMR Shareholding/SIP and TVR.
About this update from Diaceutics Plc
[{"type":"text","content":"\n\n \nDiaceutics PLC\n \nPDMR Shareholding/Share Incentive Plan and Total Voting Rights\n \nBelfast and London, 29 July 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, has been notified that on 29 July 2024, Global Shares Trustees (UK) Limited (the \"UK Trust\") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares of £0.002 in the capital of the Company (\"Shares\") on behalf of Susanne Munksted, Jordan Clark, Julie Browne, Nick Roberts and Jillian Beggs (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan (\"the SIP Schemes\") for employees. These purchases will be made each month until further notice.\n \nIn accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.\n \nAs announced on 2 October 2023, application was made to AIM for a block listing of 1,500,000 Shares to facilitate the admission of the Shares to trading following the exercise of options inter alia under the SIP Schemes. Therefore, the matched share awards for the UK PDMRs, along with those for all other participants in the UK SIP Scheme, have been settled by the Company issuing 6,859 Shares on 29 July 2024 to the UK Trust. The Trust will hold these Shares on behalf of participants until they vest in accordance with the UK Scheme rules.\n \nFollowing the issue of Shares on 29 July 2024, Diaceutics has 84,726,935 Shares in issue. This figure may be used by shareholders in the Company as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \nEnquiries:\n\n\n\n\n \nDiaceutics PLC \n\n\n \nTel: +44 (0)28 9040 6500 \n\n\n\n\nNick Roberts, Chief Financial Officer \n\n\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\nStifel Nicolaus Europe Limited (Nomad & Broker)\n\n\nTel: +44 (0)20 7710 7600\n\n\n\n\nBen Maddison\n\n\n\n\n\n\n\nNick Harland\n\n\n\n\n\n\n\n...